$4.8 million NIH study will teach an old drug to maintain its tricks

July 27, 2015

DETROIT - With the decline of the development of new antibiotics due to the complexity and expense of discovering them, there has been a rapid growth of antibiotic resistant pathogens that is one of the leading causes of death. With the help of a nearly $4.9 million, 5-year grant from the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, Wayne State University School of Medicine researchers are leading a landmark multi-center, international study that will provide essential information to clinicians for use of polymoxin B in critically ill patients where no other treatments will work.

The study, "Optimizing clinical use of polymyxin B: teaching an old drug to treat superbugs," will focus on Gram-negative bacteria resistant to all other antibiotics except polymyxin B. Keith Kaye, M.D., professor of infectious diseases will lead the study that includes collaborators from Australia and Singapore.

"Our study will provide urgently needed information to guide clinicians in the proper intravenous dosing of polymyxin B in critically-ill patients," said Kaye. "It is critical to have these dosing guides to assure that this agent of last resort is preserved and that these superbugs do not become resistant to it. These guides will aid in minimizing unnecessary toxic side effects of the drug."

Since its release in the 1950s, there has been no clear definition of how to dose polymyxin B optimially, and how to minimize the emergence of resistance to this drug. Recent studies on polymyxins have focused on colistin methanesulfonate (CMS). These studies have demonstrated that CMS has significant limitations, and therefore dosage recommendations for CMS should not be applied to polymyxin B. Polymyxin B has fewer limitations than does CMS.

The team will focus on defining the optimal dosage regimens by determining the association between dose and the timing of nephrotoxicity and use of next-generation proteomics to identify the most predictive biomarkers of polymyxin B associated nephrotoxicity. One of the most exciting components of the study is to develop therapeutic drug monitoring systems to assist physicians in optimizing polymyxin B dose and minimizing toxicity.

"Patients being treated with intravenous polymyxin B will be identified, and will have blood collected at various times surrounding a dose of polymyxin B between days 1 and 5 of therapy," said Kaye. "Development of nephrotoxicity, clinical response and bacteriological response will be examined. Total and free plasma concentrations of polymyxin B will be determined, and bacterial isolates will be examined for the emergence of polymyxin resistance."

Life-threatening infections caused by the Gram-negative superbugs that become resistant to polymyxin B are practically untreatable. The results from this study will provide critical information that will guide clinicians in the proper intravenous dosing of polymyxin B in critically ill patients, ultimately preserving the usefulness of the drug and maintaining its stature as an essential agent of last resort.
-end-
Collaborators on the grant include Jason Pogue, PharmD of Sinai Grace Hospital, DMC; Jian Li, Ph.D. of Monash University, Australia; and Alan Forrest, PharmD of the University of North Carolina.

The grant number for this National Institutes of Health award is AI119446.

About Wayne State University

Wayne State University is one of the nation's pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://research.wayne.edu.

Wayne State University - Office of the Vice President for Research

Related Infectious Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Forecasting elections with a model of infectious diseases
Election forecasting is an innately challenging endeavor, with results that can be difficult to interpret and may leave many questions unanswered after close races unfold.

COVID-19 a reminder of the challenge of emerging infectious diseases
The emergence and rapid increase in cases of coronavirus disease 2019 (COVID-19), a respiratory illness caused by a novel coronavirus, pose complex challenges to the global public health, research and medical communities, write federal scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and from the Centers for Disease Control and Prevention (CDC).

Certain antidepressants could provide treatment for multiple infectious diseases
Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.

Opioid epidemic is increasing rates of some infectious diseases
The US faces a public health crisis as the opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin and soft tissue infections.

Infectious diseases could be diagnosed with smartphones in sub-Saharan Africa
A new Imperial-led review has outlined how health workers could use existing phones to predict and curb the spread of infectious diseases.

The Lancet Infectious Diseases: Experts warn of a surge in vector-borne diseases as humanitarian crisis in Venezuela worsens
The ongoing humanitarian crisis in Venezuela is accelerating the re-emergence of vector-borne diseases such as malaria, Chagas disease, dengue, and Zika virus, and threatens to jeopardize public health gains in the country over the past two decades, warn leading public health experts.

Glow-in-the-dark paper as a rapid test for infectious diseases
Researchers from Eindhoven University of Technology (The Netherlands) and Keio University (Japan) present a practicable and reliable way to test for infectious diseases.

Math shows how human behavior spreads infectious diseases
Mathematics can help public health workers better understand and influence human behaviors that lead to the spread of infectious disease, according to a study from the University of Waterloo.

Many Americans say infectious and emerging diseases in other countries will threaten the US
An overwhelming majority of Americans (95%) think infectious and emerging diseases facing other countries will pose a 'major' or 'minor' threat to the U.S. in the next few years, but more than half (61%) say they are confident the federal government can prevent a major infectious disease outbreak in the US, according to a new national public opinion survey commissioned by Research!America and the American Society for Microbiology.

Read More: Infectious Diseases News and Infectious Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.